Imagion set to complete the MagSense HER2 Phase 1 Study
Posted: 21 June 2023 Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that the MagSense® HER2 imaging agent Phase 1 study (IBI10103) has achieved its enrolment…
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Posted: 21 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,680,104) by the United States Patent Office.…
Rhythm Continues Platform Expansion Program for Other Cancers
Posted: 21 June 2023 Transformative cancer diagnostic technology, Rhythm Biosciences Ltd is pleased to provide an update regarding the technical feasibility pipeline expansion initiatives/opportunities. As previously announced, the Company has identified several other critical cancers where it can…
Vaccine Innovation Trends Report: Global Vaccine Research and Development Pipeline and Delivery Implications
Posted: 19 June 2023 Vaccines are essential to global public health — available to prevent more than 20 diseases, vaccines avert 3.5 to 5 million deaths each year and combat emerging infectious diseases and the spread of microbial…
U.S. FDA Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Posted: 19 June 2023 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3 VALOR-HCM study to the U.S.…
Pioneering radiotherapy treatment emerging as a new option for cancers spread to lungs
Posted: 19 June 2023 A pioneering radiotherapy treatment developed at Peter Mac is emerging as a new treatment option for cancer that has spread to the lungs, following exciting results in a recent study. Long-term survival data is…
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
Posted: 19 June 2023 Telix today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of…
Why this CEO thinks 454pc growth in his company is just the beginning
Posted: 15 June 2023 Telix Pharmaceuticals has topped the inaugural Financial Review Fast Global list, with international revenue growth at the Melbourne-based, cancer-fighting biotech soaring off the back of a drug approval in the US. The Fast Global…
Telix Opens European Radiopharmaceutical Production Facility
Posted: 13 June 2023 Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production facility located in…
RMIT backs Vietnam with new $250m strategic investment fund
Posted: 13 June 2023 Today, in the presence of Australia’s Prime Minister, the Honourable Anthony Albanese MP, RMIT University announced the next phase of its Country Commitment to Vietnam, including a AUD $250 million strategic investment fund. The…
New Eye Clinical Trials Centre to Give Victorians World-First Treatments
Posted: 13 June 2023 Breakthrough Victoria is investing $10 million towards a new world-leading eye clinical trials centre that will provide Victorians with early access to new treatments aiming to prevent and cure blindness. The new eye clinical…
Clinical trials in Australia to use common voice
Posted: 9 June 2023 ARCS Australia has released a white paper to define common terms used in decentralised clinical trials providing a common and consistent language for the sector. The paper was released on day two of the…
